Federated Hermes, Inc. Cullinan Oncology, Inc. Transaction History
Federated Hermes, Inc.
- $43.9 Billion
- Q1 2025
A detailed history of Federated Hermes, Inc. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,458 shares of CGEM stock, worth $21,482. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,458
Previous 3,802
35.35%
Holding current value
$21,482
Previous $46,000
60.87%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$66.8 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$50.3 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$33.7 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$31 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.8 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $399M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...